AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Symptoms and Physical Activity in COPD Patients in Europe
Completed
- Conditions
- COPD
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2176
- Registration Number
- NCT03031769
- Locations
- 🇷🇴
Research site, Iasi, Romania
Bioavailability of AZD0284 and IV Microtracer Study
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT03029741
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
Phase 1
Completed
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT03022409
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
Phase 3
Completed
- Conditions
- COPD
- Interventions
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1625
- Registration Number
- NCT03022097
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT03019549
- Locations
- 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Phase 3
Active, not recruiting
- Conditions
- Non Small Cell Lung Carcinoma NSCLC
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 669
- Registration Number
- NCT03003962
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
T790M Plasma Testing Methodology Comparison and Clinical Validation
Phase 3
Completed
- Conditions
- Lung Cancer
- Interventions
- Procedure: T790M+ TestingProcedure: Baseline Visit Blood & Urine TestingProcedure: Baseline ECGProcedure: Visual Slit-Lamp TestingDrug: AZD9291 DosingProcedure: Plasma AZD9291 testing
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 256
- Registration Number
- NCT02997501
- Locations
- 🇨🇳
Research Site, Xi'an, China
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
Completed
- Conditions
- Diabetes Mellitus Type 2
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99999
- Registration Number
- NCT02993614
- Locations
- 🇬🇧
Research Site, Luton, D1690r00015, United Kingdom
ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory
Completed
- Conditions
- Locally Advanced or Metastatic EGFR(+) NSCLC Patients
- Interventions
- Procedure: genomic testing of T790M mutation
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 897
- Registration Number
- NCT02991274
- Locations
- 🇨🇳
Research Site, Ürümqi, China
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
Phase 3
Completed
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 387
- Registration Number
- NCT02987543
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath